Initiates Coverage on NovaBay Pharmaceuticals (NYSE:NBY) assumed coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY – Free Report) in a research note issued to investors on Sunday. The firm set a 'hold' rating on the stock. NovaBay…

In a Sunday research note, the firm issued a 'hold' rating on the stock. The stock was given a rating of 'hold' by the firm.

NovaBay Pharmaceuticals Company profile

Free Report

NovaBay Pharmaceuticals, Inc., a biopharmaceutical firm, develops, manufactures, and markets eyecare, skin care, and wound-care products both in the United States as well as internationally. Avenova Spray is a solution that removes microorganisms from the skin around the eyes, such as on the eyelid. Wound care products are also available under the NeutroPhase or PhaseOne brand. They can be used to cleanse and irrigate wounds as part of surgery, and treat certain injuries, wounds, burns and ulcers. offers a FREE daily email newsletter